These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 37319398)

  • 1. Rational Design and Efficacy of Glucose-Responsive Insulin Therapeutics and Insulin Delivery Systems by Computation Using Connected Human and Rodent Models.
    Yang S; Yang JF; Gong X; Weiss MA; Strano MS
    Adv Healthc Mater; 2023 Oct; 12(25):e2300587. PubMed ID: 37319398
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Connecting Rodent and Human Pharmacokinetic Models for the Design and Translation of Glucose-Responsive Insulin.
    Yang JF; Gong X; Bakh NA; Carr K; Phillips NFB; Ismail-Beigi F; Weiss MA; Strano MS
    Diabetes; 2020 Aug; 69(8):1815-1826. PubMed ID: 32152206
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rational Design of Glucose-Responsive Insulin Using Pharmacokinetic Modeling.
    Bakh NA; Bisker G; Lee MA; Gong X; Strano MS
    Adv Healthc Mater; 2017 Nov; 6(22):. PubMed ID: 28841775
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In Silico Investigation of the Clinical Translatability of Competitive Clearance Glucose-Responsive Insulins.
    Yang JF; Yang S; Gong X; Bakh NA; Zhang G; Wang AB; Cherrington AD; Weiss MA; Strano MS
    ACS Pharmacol Transl Sci; 2023 Oct; 6(10):1382-1395. PubMed ID: 37854621
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent Progress in Glucose-Responsive Insulin.
    Liu Y; Wang S; Wang Z; Yu J; Wang J; Buse JB; Gu Z
    Diabetes; 2024 Sep; 73(9):1377-1388. PubMed ID: 38857114
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of glucose-responsive 'smart' insulin systems.
    Rege NK; Phillips NFB; Weiss MA
    Curr Opin Endocrinol Diabetes Obes; 2017 Aug; 24(4):267-278. PubMed ID: 28509691
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Superior Glycemic Control With a Glucose-Responsive Insulin Analog: Hepatic and Nonhepatic Impacts.
    Moore MC; Kelley DE; Camacho RC; Zafian P; Ye T; Lin S; Kaarsholm NC; Nargund R; Kelly TM; Van Heek M; Previs SF; Moyes C; Smith MS; Farmer B; Williams P; Cherrington AD
    Diabetes; 2018 Jun; 67(6):1173-1181. PubMed ID: 29540491
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glucose-Responsive Insulin Through Bioconjugation Approaches.
    Disotuar MM; Chen D; Lin NP; Chou DH
    J Diabetes Sci Technol; 2020 Mar; 14(2):198-203. PubMed ID: 31216874
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An Aldehyde Responsive, Cleavable Linker for Glucose Responsive Insulins.
    Mannerstedt K; Mishra NK; Engholm E; Lundh M; Madsen CS; Pedersen PJ; Le-Huu P; Pedersen SL; Buch-Månson N; Borgström B; Brimert T; Fink LN; Fosgerau K; Vrang N; Jensen KJ
    Chemistry; 2021 Feb; 27(9):3166-3176. PubMed ID: 33169429
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in the glycaemia risk index and its association with other continuous glucose monitoring metrics after initiation of an automated insulin delivery system in adults with type 1 diabetes.
    Karakus KE; Shah VN; Klonoff D; Akturk HK
    Diabetes Obes Metab; 2023 Nov; 25(11):3144-3151. PubMed ID: 37427768
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ultrahigh performance liquid chromatography methods facilitate the development of glucose-responsive insulin therapeutics.
    Jia X; Meng F; Pickens CJ; Thaisrivongs D; Yan L; Huo P; Maloney KM; Lin S
    Anal Bioanal Chem; 2020 Jan; 412(2):377-388. PubMed ID: 31773226
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Developing Insulin Delivery Devices with Glucose Responsiveness.
    Wang Z; Wang J; Kahkoska AR; Buse JB; Gu Z
    Trends Pharmacol Sci; 2021 Jan; 42(1):31-44. PubMed ID: 33250274
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glycemic variability through the perspective of the glycemia risk index and time in range and their association with glycated hemoglobin A1c in pediatric patients on sensor-augmented pump therapy.
    Bukara-Radujkovic G; Miljkovic V
    Front Endocrinol (Lausanne); 2024; 15():1388245. PubMed ID: 38957442
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glycemic Risk Index Profiles and Predictors Among Diverse Adults With Type 1 Diabetes.
    Hoogendoorn CJ; Hernandez R; Schneider S; Harmel M; Pham LT; Crespo-Ramos G; Agarwal S; Crandall J; Peters AL; Spruijt-Metz D; Gonzalez JS; Pyatak EA
    J Diabetes Sci Technol; 2024 Sep; 18(5):1070-1078. PubMed ID: 36999215
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Erythrocyte-Membrane-Enveloped Biomineralized Metal-Organic Framework Nanoparticles Enable Intravenous Glucose-Responsive Insulin Delivery.
    He M; Yu P; Hu Y; Zhang J; He M; Nie C; Chu X
    ACS Appl Mater Interfaces; 2021 May; 13(17):19648-19659. PubMed ID: 33890785
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Type 1 diabetes glycemic management: Insulin therapy, glucose monitoring, and automation.
    Perkins BA; Sherr JL; Mathieu C
    Science; 2021 Jul; 373(6554):522-527. PubMed ID: 34326234
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glycemia Risk Index Assessment in a Pediatric and Adult Patient Cohort With Type 1 Diabetes Mellitus.
    Díaz-Soto G; Pérez-López P; Férnandez-Velasco P; Nieto de la Marca MO; Delgado E; Del Amo S; de Luis D; Bahillo-Curieses P
    J Diabetes Sci Technol; 2024 Sep; 18(5):1063-1069. PubMed ID: 36794818
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Microneedle-array patches loaded with hypoxia-sensitive vesicles provide fast glucose-responsive insulin delivery.
    Yu J; Zhang Y; Ye Y; DiSanto R; Sun W; Ranson D; Ligler FS; Buse JB; Gu Z
    Proc Natl Acad Sci U S A; 2015 Jul; 112(27):8260-5. PubMed ID: 26100900
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glucose transporter inhibitor-conjugated insulin mitigates hypoglycemia.
    Wang J; Yu J; Zhang Y; Kahkoska AR; Wang Z; Fang J; Whitelegge JP; Li S; Buse JB; Gu Z
    Proc Natl Acad Sci U S A; 2019 May; 116(22):10744-10748. PubMed ID: 31097579
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glucose-responsive nanoparticles designed via a molecular-docking-driven method for insulin delivery.
    Shen D; Yu H; Wang L; Feng J; Zhang Q; Pan J; Han Y; Ni Z; Liang R; Uddin MA
    J Control Release; 2022 Dec; 352():527-539. PubMed ID: 36341933
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.